Dernières nouvelles pour Azenta (NASDAQ:AZTA) Stock

Azenta

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.

Azenta Inc

Azenta Life Sciences Storage System selected by UK Biocentre

Azenta: Taking A Pass

Azenta Q1 2025 Earnings Preview

New insider activity at Azenta ( ($AZTA) ) has taken place on February 5, 2025. Violetta Hughes, the Vice President and Chief Accounting Officer at...

Top Executive Sells Azenta Shares in Noteworthy Transaction

Azenta beats Q1 top-line and bottom-line estimates; reaffirms FY25 outlook

Analyst David Saxon of Needham reiterated a Buy rating on Azenta (AZTA – Research Report), boosting the price target to $59.00. David Saxon has giv...

Azenta's Promising Growth and Strong Financial Performance Lead to Buy Rating

Azenta reiterates 2025 guidance with 3-5% organic growth and EBITDA margin expansion

Azenta, Inc. 2025 Q1 - Results - Earnings Call Presentation

Azenta, Inc. (AZTA) Q1 2025 Earnings Call Transcript

Azenta, Inc. ( ($AZTA) ) has released its Q1 earnings. Here is a breakdown of the information Azenta, Inc. presented to its investors. Azenta, Inc....

Azenta, Inc. Reports Strong Q1 2025 Results

AZTA

TWST

Press Releases

Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test

Azenta Announces the Addition of Three New Independent Directors Effective Immediately and New Initiative to Drive Value

Azenta Announces Fiscal 2024 Fourth Quarter and Full Year Earnings Conference Call and Webcast

Earnings

Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO

Azenta to Participate in Stephens Annual Investment Conference

Mutual Funds

Markets

Flex Set to Join S&P MidCap 400; Azenta and Concentra Group Holdings to Join S&P SmallCap 600

UK Biocentre Selects the Azenta Life Sciences BioArc Ultra Automated Storage System to Advance Research Excellence

Azenta Announces Fiscal 2025 First Quarter Earnings Conference Call and Webcast

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Azenta Reports First Quarter Results for Fiscal 2025, Ended December 31, 2024

FLEX

LVWR

SPGI

TRDA

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Azenta

Actualités

Dernières nouvelles pour Azenta (NASDAQ:AZTA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL